Table 3. Anti-diabetic and anti-hypertensive treatment in intervention group and in control group at baseline and at 12-month follow-up (FU).
| Total | Intervention group | Control Group |
p-value | |
|---|---|---|---|---|
| At baseline | n = 151 | n = 76 | n = 75 | |
| Insulin | 43 (28.5%) | 22 (28.9%) | 21 (28.0%) | 0.90 |
| OAD only* | 108 (71.5%) | 55 (72.4%) | 53 (70.7%) | 0.82 |
| Combination of 2 OADs** | 108 (71.5%) | 55 (72.4%) | 53 (70.7%) | 0.82 |
| Calcium channel blockers | 7 (4.6%) | 5 (6.6%) | 2 (2.7%) | 0.44 |
| Beta Blockers | 4 (2.6%) | 2 (2.6%) | 2 (2.7%) | 0.99 |
| Angiotensin Receptor Blockers | 23 (15.2%) | 15 (19.7%) | 8 (10.7%) | 0.12 |
| Central | 1 (0.7%) | 1 (1.3%) | 0 (0.0%) | 1.00 |
| Diuretics | 1 (0.7%) | 1 (1.3%) | 0 (0.0%) | 1.00 |
| At the end of FU | n = 140 | n = 70 | n = 70 | |
| Insulin | 36 (25.7%) | 17 (24.3%) | 19 (27.1%) | 0.70 |
| OAD* only | 102 (72.9%) | 51 (72.9%) | 51 (72.9%) | 1.00 |
| Combination** of 2 OADs | 100 (71.4%) | 50 (71.4%) | 50 (71.4%) | 1.00 |
| Calcium channel blockers | 11 (7.9%) | 6 (8.6%) | 5 (7.1%) | 0.75 |
| Beta Blockers | 6 (4.3%) | 3 (4.3%) | 3 (4.3%) | 1.00 |
| Angiotensin Receptor Blockers | 36 (25.7%) | 22 (31.4%) | 14 (20.0%) | 0.12 |
| Central | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NC |
| Diuretics | 3 (2.1%) | 1 (1.4%) | 2 (2.9%) | 1.00 |
Data are n (%)
*OAD: Oral Antidiabetic therapy comprising metformin and/or sulfonylurea and/or alpha-glucosidase inhibitors.
**Combination of 2 OAD: Combination of metformin and sulfonylurea